AbCellera Biologics Inc
(NAS:ABCL)
$
2.995
0.045 (1.53%)
Market Cap: 871.33 Mil
Enterprise Value: 299.59 Mil
PE Ratio: 0
PB Ratio: 0.81
GF Score: 66/100 Abcellera Biologics Inc at Bank of America Tech Solutions for Drug Discovery Conference (Virtual) Transcript
Sep 20, 2021 / 04:00PM GMT
Release Date Price:
$20.65
(+1.42%)
Michael Leonidovich Ryskin
BofA Securities, Research Division - Associate
Okay. We're kicking off our next session here at the BofA Tech-enabled Drug Discovery Conference. Thank you for joining us. My name is Mike Ryskin. I'm on the life science tools and diagnostics team. Joining me here is the senior analyst on the team, Derik De Bruin. And for our next session, we're excited to have AbCellera Biologics joining us. With us, we have CEO and Co-Founder, Carl Hansen. Carl, thank you for being here.
Carl L.G. Hansen
AbCellera Biologics Inc. - President, CEO & Director
My pleasure. Thanks, Michael.
Michael Leonidovich Ryskin
BofA Securities, Research Division - Associate
Great. And to get going here, we're going to have a brief presentation to start, where Carl will take us through some of the background and then we'll go to a fireside chat format after that. So Carl, kicking it up to you.
Carl L.G. Hansen
AbCellera Biologics Inc. - President, CEO & Director
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot